<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609973</url>
  </required_header>
  <id_info>
    <org_study_id>Cipro 1.1</org_study_id>
    <nct_id>NCT00609973</nct_id>
  </id_info>
  <brief_title>Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease</brief_title>
  <official_title>Double-blind, Placebo Controlled, Randomized, Multicentre, Pilot Study on the Safety and Efficacy of Ciprofloxacin for Prophylactic Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite extensive medical treatment, surgical resection is required in approximately 70% of
      the patients at some time. However, recurrence of the disease after operation occurs in the
      majority of patients and is a serious limitation of surgical management. Therapeutic options
      to maintain postoperative clinical remission are urgently needed. Several drugs including
      mesalazine, antibiotics (metronidazole, ornidazole) and azathioprine or 6-mercaptopurine have
      been studied in the past. But the efficacy is very limited (mesalazine), overshadowed by
      intolerability during long-term therapy (metronidazole, ornidazole) or inconclusive
      (azathioprine or 6-mercaptopurine). Research demonstrating the absence of inflammation in
      patients with diverting ileostomy and the clinical benefit of a postoperative antibiotic
      therapy using metronidazole or ornidazole implicates a role of the resident bacterial flora
      in the postoperative relapse. Ciprofloxacin has a broad antibacterial spectrum. More
      interestingly it also suppresses E. coli strains, which can be found in high numbers in early
      and chronic ileal lesions of Crohn's disease patients Ciprofloxacin has demonstrated
      beneficial effects in the therapy of inflammatory bowel diseases, but the available data of
      the effectiveness of ciprofloxacin allow only a very limited judgement of the safety and
      tolerability of a 6 months therapy of ciprofloxacin. Therefore an exploratory multicenter
      prospective, placebo-controlled trial is planned to analyze the safety and tolerability of a
      6 months therapy with ciprofloxacin compared to placebo in 40 patients (randomly assigned in
      a 1:1 ratio) undergoing ileocecal resection (or resection of parts of the colon). If this
      therapeutic regimen demonstrates tolerability, a second larger study improving the
      superiority of ciprofloxacin versus placebo can be initiated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite extensive medical treatment, surgical resection is required in approximately 70% of
      the patients at some time. However, recurrence of the disease after operation occurs in the
      majority of patients and is a serious limitation of surgical management. In this setting the
      bacterial flora plays an important role as demonstrated by the benefit of a postoperative
      antibiotic therapy with either metronidazole or ornidazole or the absence of inflammation in
      patients with diverting ileostomy. However, both aforementioned antibiotic regimens have
      numerous adverse events limiting the value of this therapy in daily clinical practice.
      Ciprofloxacin suppresses the gram negative aerobic bacterial flora including E.coli strains,
      which can be found in early and chronic ileal lesions of Crohn's disease patients. A limited
      number of clinical data suggest efficacy of this drug in patients with established Crohn's
      disease. This exploratory multicenter prospective, placebo-controlled trial will analyze the
      safety and tolerability of a 6 months therapy with ciprofloxacin compared to placebo in 40
      patients (randomly assigned in a 1:1 ratio) undergoing ileocecal resection (or resection of
      parts of the colon) with primary anastomosis. No other treatments for Crohn's disease will be
      permitted. The primary objective of this study is to assess the safety and tolerability of a
      6 months therapy of ciprofloxacin (500 mg bid) vs. placebo tablets for prevention of
      endoscopic recurrence in postoperative Crohn's disease patients. The secondary objectives of
      this study are to evaluate the endoscopic recurrence in the neoterminal ileum and at the
      ileocolonic anastomosis as well as the extent of colonic lesions. Additionally bioptic
      samples at the anastomotic site and patient DNA samples will be collected for later analysis
      of bacterial ribosomal 19S RNA and DNA polymorphisms (such as NOD2 or IL-23). The clinical
      data generated by this study will serve as a basis for a definitive clinical trial
      investigating the effectiveness of ciprofloxacin in the prevention of endoscopic recurrence
      in postoperative Crohn's disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Ciprofloxacin</measure>
    <time_frame>6 Months</time_frame>
    <description>Adverse events (AE) Discontinuation of study drug due to probably study drug related AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Recurrence Under Postoperative Treatment With Study Medication at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 500 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Ciprofloxacin 500 mg oral bid for 6 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo bid for 6 months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Man or woman between 18 and 70 years of age.

          -  Diagnosis of Crohn's disease confirmed during index surgery.

          -  Detailed assessment of disease localization by colonoscopy, small bowel radiography,
             and/or other appropriate methods (e.g., MRI, CT) within 6 months prior inclusion into
             the study.

          -  Resection for ileal or ileo-colonic Crohn's disease with ileo-colonic anastomosis
             (i.e., without grossly visible disease at the resection margins); neoterminal ileum
             should be assessable by endoscopy.

          -  Ability to start oral nutrition and medication intake within 14 days after index
             surgery.

          -  Negative pregnancy test at screening visit in females of childbearing potential.

          -  Use of appropriate contraceptive methods for females of childbearing potential and
             males with procreative capacity during treatment.

        Exclusion Criteria:

          -  Short bowel syndrome.

          -  Previous long term therapy with ciprofloxacin (&gt; 6 weeks prior before surgery)

          -  Patients in whom any visible lesions at the anastomosis were left after index surgery.

          -  Serious secondary illnesses of an acute or chronic nature, which in the opinion of the
             Investigator renders the patient unsuitable for inclusion into the study.

          -  Dementia

          -  Uncontrolled Diabetes Type I type II

          -  Known drug abuse

          -  Known parasitic disease of the digestive system

          -  Active replicating Hepatitis B or Hepatitis C

          -  HIV-infection

          -  Seizure disorder

          -  Serum creatinine levels exceeding 1.5 mg/dL or 130 Î¼mol/L.

          -  Presence of an ileal or colonic stoma.

          -  Known previous or concurrent malignancy (other than that considered surgically cured,
             with no evidence for recurrence for 5 years).

          -  Application of non-steroidal anti-inflammatory drugs as long term treatment.

          -  Known intolerance/hypersensitivity to ciprofloxacin or other quinolones or drugs of
             similar chemical structure or pharmacological profile.

          -  Chronic use of CYP1A2 substrates (aminophylline, fluvoxamine, mexiletine, mirtazapine,
             ropinirole, tizanidine, trifluoperazine)

          -  Well-founded doubt about the patient's cooperation.

          -  Existing pregnancy, lactation, or intended pregnancy or impregnation within the next 3
             months.

          -  Non-use of appropriate contraceptives in females of childbearing potential (e.g.
             condoms, intrauterine device [IUD], hormonal contraception for females, or a means of
             contraception for a particular patient considered adequate by the responsible
             investigator) during treatment.

          -  Participation in another clinical trial within the last 30 days, simultaneous
             participation in another clinical trial, or previous participation in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans H Herfarth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>November 12, 2012</results_first_submitted>
  <results_first_submitted_qc>March 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Hans Herfarth, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Postoperative recurrence, inflammatory bowel disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was a pilot multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of ciprofloxacin for the prevention of postoperative recurrence in patients with CD. The study was conducted at 6 centers between January 2008 and March 2011. 33 patients were randomized.</recruitment_details>
      <pre_assignment_details>There were no significants events pre-assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cipro</title>
          <description>Ciprofloxacin 500 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cipro</title>
          <description>Ciprofloxacin 500 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo bid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="19" upper_limit="70"/>
                    <measurement group_id="B2" value="27" lower_limit="18" upper_limit="61"/>
                    <measurement group_id="B3" value="30" lower_limit="18" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Ciprofloxacin</title>
        <description>Adverse events (AE) Discontinuation of study drug due to probably study drug related AE</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to Treat analysis.Adverse events (AE), which were classified as probably or possibly related to the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cipro</title>
            <description>Ciprofloxacin 500 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo bid</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Ciprofloxacin</title>
          <description>Adverse events (AE) Discontinuation of study drug due to probably study drug related AE</description>
          <population>Intention to Treat analysis.Adverse events (AE), which were classified as probably or possibly related to the study drug.</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE probably or possibly related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant stops study drug due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Recurrence Under Postoperative Treatment With Study Medication at 6 Months</title>
        <time_frame>6 months</time_frame>
        <population>Endoscopy 6 months, Intention-to-Treat analysis, patients not undergoing endoscopy were assumed to have endoscopic recurrence</population>
        <group_list>
          <group group_id="O1">
            <title>Cipro</title>
            <description>Ciprofloxacin 500 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo bid</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Recurrence Under Postoperative Treatment With Study Medication at 6 Months</title>
          <population>Endoscopy 6 months, Intention-to-Treat analysis, patients not undergoing endoscopy were assumed to have endoscopic recurrence</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cipro</title>
          <description>Ciprofloxacin 500 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leakage</sub_title>
                <description>Anastomotic leakage after surgery</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increase of diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Wound healing problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hans Herfarth</name_or_title>
      <organization>University of North Carolina</organization>
      <phone>9199666806</phone>
      <email>hherf@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

